Tanvex BioPharma Inc
TWSE:6541
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.95
74.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tanvex BioPharma Inc
Tanvex BioPharma Inc
Other Equity
Tanvex BioPharma Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Other Equity
-NT$198.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
SSE:688235
|
Other Equity
¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Polaris Group
TWSE:6550
|
Other Equity
NT$381.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tanvex BioPharma Inc
Glance View
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.
See Also
What is Tanvex BioPharma Inc's Other Equity?
Other Equity
-198.1m
TWD
Based on the financial report for Sep 30, 2024, Tanvex BioPharma Inc's Other Equity amounts to -198.1m TWD.
What is Tanvex BioPharma Inc's Other Equity growth rate?
Other Equity CAGR 5Y
0%
Over the last year, the Other Equity growth was -22%. The average annual Other Equity growth rates for Tanvex BioPharma Inc have been 20% over the past three years .
You don't have any saved screeners yet
